RESVINET
  • Home
  • About RSV
    • professionals
    • Publications
  • about us
    • The foundation
    • ReSViNET Team
    • contact us >
      • Support us >
        • Webshop
        • Donate
  • Conference
    • RSVVW'23
    • Previous conferences >
      • RSVVW'21
      • RSVVW'19
      • 4th Meeting 2017
      • 3rd Meeting 2017
      • 2nd Expert Meeting
      • 1st Expert Meeting
  • Webinar Series
  • patient network
    • Activities >
      • Webinars
    • RSV Awareness Week
    • Patient Advisory Board
    • Promise
    • RSV reading material
    • contact patient network
  • Home
  • About RSV
    • professionals
    • Publications
  • about us
    • The foundation
    • ReSViNET Team
    • contact us >
      • Support us >
        • Webshop
        • Donate
  • Conference
    • RSVVW'23
    • Previous conferences >
      • RSVVW'21
      • RSVVW'19
      • 4th Meeting 2017
      • 3rd Meeting 2017
      • 2nd Expert Meeting
      • 1st Expert Meeting
  • Webinar Series
  • patient network
    • Activities >
      • Webinars
    • RSV Awareness Week
    • Patient Advisory Board
    • Promise
    • RSV reading material
    • contact patient network

Publications

No more antibiotics for viral respiratory infections

2/4/2015

0 Comments

 
A Novel Host-Proteome Signature For Distinguishing Between Acute Bacterial AndViral Infections - Oved K, Cohen A, Boico  O, et al

A Multifaceted ‘Omics’ Approach For Addressing The Challenge Of Antimicrobial Resistance - Cohen A, Bont L, Engelhard D, et al

A simple blood test distinguishes between bacterial and viral infections. Oved identified  novel viral-induced host proteins able to complement bacterial-induced proteins to increase diagnostic accuracy. A bioinformatic screen identified putative circulating host immune response proteins which were tested in more than 1000 patients. The best performing combination of host-proteins were TNF-related apoptosis-inducing ligand (TRAIL, Interferon gamma-induced protein (IP)-10 and CRP (AUC of 0.94; 95% CI, 0.92 to 0.96). The signature was superior to any of the individual proteins, routinely used clinical parameters and their combinations. It remained robust across different physiological systems, times from symptom onset, and pathogens (AUCs 0.87-1.0). In collaboration with John Hays from Erasmus Mc in Rotterdam, the Netherlands and other European researchers the authors have now initiated a multilevel –omics approach to further develop sensitive and specific tools to target antibiotics for respiratory tract infections. The accurate diagnosis of viral versus bacterial infection has the potential to improve management of patients with acute infections and reduce antibiotic misuse.

Download Oved et al.
Download Cohen et al.
0 Comments

    CATEGORIES

    All
    ReSViNET Publications


    ARCHIVES

    March 2023
    January 2023
    April 2022
    February 2022
    September 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    March 2020
    January 2020
    December 2019
    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    April 2018
    December 2017
    May 2017
    March 2017
    February 2017
    September 2016
    June 2016
    March 2016
    November 2015
    October 2015
    September 2015
    June 2015
    May 2015
    April 2015
    March 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014


    RSS Feed

Note: All information on ReSViNET is for educational purposes only. For specific medical advice, diagnoses, and treatment, consult your doctor.

© 2021 ReSViNET Foundation. All rights reserved.
About us
Disclosure
Contact